Home News International

International

Glenmark Pharma opens new facility in Switzerland

New Delhi, June 10, 2014 - Glenmark Pharmaceuticals, on Wednesday, said its wholly-owned subsidiary, Glenmark Pharmaceuticals S.A., opened its new cGMP (current good manufacturing practice)-compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. An antibody or immunoglobulin is a...

WACKER Opens Logistics Center at Amtala Production Site

Amtala, July 9, 2014 – The Munich-based chemical group WACKER announced the opening of a new logistics facility at its production site in Amtala near Kolkata today. The high-bay warehouse has a capacity of 5000 pallet spaces and will...

Dr Reddy’s launches anti-depressant generic in US

HYDERABAD, July 05, 2014 : Pharma major Dr Reddy's Laboratories has launched Duloxetine delayed release capsules in the US market. The anti-depressant drug is the generic equivalent of Cymbalta. The brand and generic had a sales of $5 billion...

Lupin launches generic Niaspan tablets in US market

New Delhi, March 22,2014 - Mumbai-based pharma major Lupin Ltd today launched its generic version of Niaspan extended release tablets, used in reducing cholesterol in the US market. The company’s US subsidiary, Lupin Pharmaceuticals Inc has launched the...

Watson Completes Actavis Acquisition

Creates 3rd largest global generics company with presence in 60+ markets$8.0+ billion anticipated pro forma combined 2012 revenueCombined management structured to immediately maximize combination value

PARSIPPANY, N.J. – October 31, 2012 – Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of the Actavis Group for EUR4.25 billion. The combination creates the world’s third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion.

Bayer HealthCare completes acquisition of Teva’s U.S. animal health business

New product lines strengthen Bayer’s animal health business in the U.S.

Leverkusen, January 4, 2013 – Bayer HealthCare announced today that it has received the necessary regulatory approval from the Federal Trade Commission to complete the acquisition of the U.S.-based animal health business of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). As announced in September 2012, Bayer will pay up to 145 million USD which includes an upfront payment of 60 million USD plus a total of 85 million USD in milestone payments, which are linked to the successful and timely achievement of manufacturing and sales targets. The transaction includes a manufacturing site in St. Joseph, Missouri and around 300 employees. 

India Signs Loan Agreements with World bank for IDA Assistance of US $ 100...

New Delhi, May 31, 2014 - Credit Agreement for World Bank (IDA) assistance of US$ 100 million for Accelerating Universal Access to Early and Effective Tuberculosis Care has been signed between the Government of India and the World Bank here...

Medical Material Database Company Launches in India; Carna Medical Database to Establish a Medical...

New Delhi, Wednesday, December 18, 2013: Konoike Transport and Medius Holdings with their head offices in Tokyo have come together in a 70-30 joint venture to launch their Indian arm Carna Medical Database Pvt. Ltd. The Indian company has...

This Iraqi braveheart survived tennis ball-sized brain tumour

Bangalore February 28, 2014:- For the very many surgeries this team of doctors has encountered,this one was different.The tumour diagnosed in the brain of a 35-year-old Iraqi woman measured 7x9 cm in diameter as big as a tennis ball.Raizya...

Bayer Submits VEGF Trap-Eye (aflibercept) for Treatment of Macular Edema Following Central Retinal Vein...

Berlin, January 7, 2013 – Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application for marketing authorization for VEGF Trap-Eye (aflibercept solution for injection) for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) to the Ministry of Health, Labour and Welfare (MHLW) in Japan. 

The submission of VEGF Trap-Eye for macular edema following CRVO is based on data from the Phase III COPERNICUS and GALILEO studies. In both studies, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters – measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart – of Best Corrected Visual Acuity (BCVA) at 24 weeks compared to baseline on the ETDRS visual acuity charts. The VEGF Trap-Eye 2 milligrams monthly group was significantly superior to the sham control group for the primary endpoint. The effects were largely maintained in the follow-up phase until week 52.